Transgene Competitors

TRGNF Stock

USD 1.59 0.00 0.00%

Transgene SA competes with LB Foster, National Vision, GMS, Sea, and Ryanair Holdings; as well as few others. The company classifies itself under Healthcare sector and is part of Biotechnology industry. Analyzing Transgene competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Transgene to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Transgene Correlation with its peers.

You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Transgene competition on your existing holdings.

Specify up to 10 symbols:

Hype

Prediction

Low	Estimated	High
1.59	1.59	1.59

Details

Intrinsic

Valuation

Low	Real	High
1.59	1.59	1.59

Details

Naive

Forecast

Low	Next	High
1.59	1.59	1.59

Details

Bollinger

Band Projection (param)

Lower	Middle Band	Upper
1.59	1.59	1.59

Details

Transgene Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Transgene and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of Transgene and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Transgene SA does not affect the price movement of the other competitor.

	FSTR	EYE	GMS	SE	RYAAY	ASLE	PVARF
FSTR		0.55	0.68	0.67	0.25	0.79	0.39	FSTR
EYE	0.55		0.54	0.26	0.27	0.62	0.29	EYE
GMS	0.68	0.54		0.72	0.23	0.65	0.53	GMS
SE	0.67	0.26	0.72		0.4	0.57	0.59	SE
RYAAY	0.25	0.27	0.23	0.4		0.36	0.47	RYAAY
ASLE	0.79	0.62	0.65	0.57	0.36		0.67	ASLE
PVARF	0.39	0.29	0.53	0.59	0.47	0.67		PVARF
	FSTR	EYE	GMS	SE	RYAAY	ASLE	PVARF

Click cells to compare fundamentals

Check Volatility

Backtest Portfolio

Risk-Adjusted Indicators

There is a big difference between Transgene Pink Sheet performing well and Transgene Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Transgene's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

	Mean Deviation	Jensen Alpha	Sortino Ratio	Treynor Ratio	Semi Deviation	Expected Shortfall	Potential Upside	Value @Risk	Maximum Drawdown
FSTR	2.18	0.44	0.26	0.32	1.64	(2.59)	6.37	(3.40)	14.55
EYE	1.89	0.10	0.02	0.29	1.96	(2.17)	4.82	(3.21)	10.35
GMS	1.41	(0.05)	0.00	0.07	1.91	(1.48)	3.02	(3.29)	9.77
SE	1.58	0.52	0.26	2.06	1.32	(1.92)	4.65	(2.50)	12.95
RYAAY	1.58	0.06	0.01	0.22	1.90	(1.61)	3.77	(3.25)	8.74
ASLE	2.29	0.15	0.08	0.19	2.55	(2.77)	6.59	(5.14)	15.01
PVARF	0.37	0.09	0.00	0.68	0.00	0.00	0.00	0.00	10.45

Unable to evaluate fundamental data of [FSTR, EYE, GMS, SE, RYAAY, ASLE, PVARF] at this time. Please try again later

All Fundamental Data

Transgene Competitive Analysis

The better you understand Transgene competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Transgene's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Transgene's competition over several years is one of the best ways to analyze its investment potential.

Better Than Average

Worse Than Peers

View Performance Chart

	TRGNF	FSTR	EYE	GMS	SE	RYAAY	ASLE	PVARF
	0.00 1.59 Transgene	1.10 27.57 FSTR	0.87 11.65 National	2.71 101.79 GMS	1.67 114.39 Sea	0.12 42.93 Ryanair	3.39 6.40 AerSale	2.22 8.81 Porvair
Market Volatility (90 Days Market Risk)	Very steady	Not too volatile	Not too volatile	Very steady	Very steady	Very steady	Slightly risky	Not too volatile
Market Performance (90 Days Performance)	Very Weak	Good	Modest	Insignificant	Solid	Insignificant	OK	OK
Odds of Financial Distress (Probability Of Bankruptcy)	Very High	Low	Low	Low	Low	Low	Low	Low
Current Valuation (Equity Enterprise Value)	Fairly Valued	Over Valued	Under Valued	Over Valued	Over Valued	Over Valued	Over Valued	Over Valued
Buy or Sell Advice (Average Analysts Consensus)	Not Available	Hold	Buy	Buy	Strong Buy	Strong Buy	Buy	Not Available
Trade Advice (90 Days Macroaxis Advice)	Hold	Strong Buy	Cautious Hold	Cautious Hold	Cautious Hold	Cautious Hold	Hold	Cautious Hold
Current Ratio	4.27 X	2.06 X	1.36 X	2.30 X	1.92 X	1.08 X	6.77 X	2.00 X
Net Asset	101.84 M	313.21 M	1.21 B	3.76 B	18.88 B	17.18 B	553.94 M	187.7 M
Profit Margin	(1.27) %	0.08 %	(0.01) %	0.04 %	0.01 %	0.11 %	0 %	0.09 %
EBITDA	(16.55 M)	26.29 M	53.12 M	577.84 M	783.5 M	3.06 B	48 K	25.87 M
Operating Margin	(1.39) %	0.06 %	0.01 %	0.07 %	0.05 %	0.33 %	0.02 %	0.11 %
Current Valuation	152.15 M	360.38 M	1.64 B	5.51 B	63.3 B	20.28 B	436.2 M	333.47 M
Price To Book	0.02 X	1.57 X	1.06 X	2.65 X	8.44 X	2.85 X	0.75 X	2.07 X
Retained Earnings	(500 M)	124.63 M	254.62 M	1.16 B	(8.6 B)	5.9 B	133.27 M	N/A
Current Asset	51 M	214.47 M	524.19 M	503.05 M	1.65 B	4.82 B	N/A	N/A
Five Year Return	N/A	0.58 %	N/A	N/A	N/A	N/A	N/A	N/A
Beta	0.79	0.83	1.42	1.68	1.53	1.39	0.23	0.82
Number Of Employees	143	1.06 K	14 K	7.62 K	62.7 K	27 K	707	7
Shares Outstanding	100.2 M	10.83 M	78.75 M	39.29 M	528.81 M	543.23 M	53.21 M	46.33 M
Cash Flow From Operations	(31.94 M)	37.38 M	173.03 M	433.25 M	2.08 B	3.16 B	(174.15 M)	18.28 M
Annual Yield	N/A	N/A	N/A	N/A	N/A	0.02 %	N/A	0.01 %
Total Debt	N/A	67.14 M	923.46 M	1.53 B	4.46 B	2.75 B	37.53 M	N/A
Return On Equity	-0.36	0.26	-0.0975	0.17	0.0135	0.19	9.0E-4	0.12
Z Score	-5.6	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return On Asset	-0.16	0.0304	0.0097	0.0714	0.0094	0.0634	0.0041	0.0693
Book Value Per Share	0.55 X	17.06 X	10.68 X	37.43 X	13.42 X	7.09 X	8.49 X	2.86 X
Number Of Shares Shorted	N/A	169.67 K	5.18 M	1.16 M	14.9 M	7.81 M	3.02 M	N/A
Current Liabilities	24 M	91.65 M	349.87 M	176.46 M	3.39 B	3.37 B	N/A	N/A
Total Asset	101.84 M	313.21 M	1.21 B	3.76 B	18.88 B	17.18 B	553.94 M	187.7 M
Debt To Equity	0.25 %	0.64 %	1.11 %	1.23 %	0.95 %	0.81 %	N/A	0.13 %
Short Ratio	N/A	4.31 X	4.61 X	4.19 X	4.86 X	5.46 X	5.02 X	N/A
Target Price	N/A	30.0	13.7	93.0	118.72	53.0	7.33	N/A
Last Dividend Paid	N/A	N/A	N/A	N/A	N/A	0.58	N/A	0.057
Shares Owned By Institutions	1.70 %	76.58 %	98.01 %	99.33 %	64.19 %	45.60 %	66.84 %	36.79 %
Market Capitalization	212.74 M	295.34 M	909.56 M	3.89 B	66.81 B	23.29 B	340.55 M	389.72 M
Price To Earning	(7.42) X	46.82 X	88.95 X	69.15 X	92.75 X	16.27 X	20.32 X	24.83 X
Price To Earnings To Growth	N/A	N/A	(2.09) X	0.73 X	0.70 X	3.53 X	N/A	N/A
Price To Sales	10.71 X	0.55 X	0.42 X	0.70 X	4.31 X	1.72 X	0.99 X	2.18 X
Net Income	(19.54 M)	1.3 M	(65.9 M)	276.08 M	162.68 M	1.92 B	(5.56 M)	14.71 M
Earnings Per Share	(0.23) X	3.87 X	(1.04) X	6.08 X	0.15 X	1.86 X	(0.02) X	0.39 X
Shares Owned By Insiders	N/A	6.36 %	1.99 %	0.67 %	28.97 %	N/A	21.50 %	2.89 %
Revenue	9.99 M	543.74 M	2.13 B	5.5 B	13.08 B	13.44 B	334.5 M	172.57 M
Working Capital	27 M	72.68 M	(1.03 M)	882.27 M	3.6 B	(573.5 M)	219.06 M	N/A
Cash And Equivalents	49.57 M	4.94 M	258.58 M	164.75 M	6.03 B	4.62 B	200.45 M	15.99 M
Cash Per Share	0.50 X	0.45 X	3.28 X	2.56 X	13.96 X	20.37 X	3.88 X	0.35 X
Gross Profit	(15.87 M)	90.75 M	1.08 B	1.49 B	5.19 B	791.1 M	152.25 M	58.98 M
Day Typical Price	1.59	27.07	11.5	100.84	114.65	43.2	6.34	8.81
Accumulation Distribution	N/A	0.0548	0.0386	0.028	0.0522	0.0221	0.0419	N/A
Market Facilitation Index	N/A	1.51	0.45	2.85	6.15	0.97	0.27	N/A
Daily Balance Of Power	0.0	0.1987	0.2222	0.9439	(0.32)	0.0515	0.7778	(9,223,372,036,855)
Period Momentum Indicator	N/A	0.3	0.1	2.69	(1.94)	0.05	0.21	(0.20)
Rate Of Daily Change	1.0	1.01	1.01	1.03	0.98	1.0	1.03	0.98
Day Median Price	1.59	26.82	11.43	100.37	114.78	43.34	6.32	8.81
Price Action Indicator	N/A	0.91	0.28	2.77	(1.35)	(0.38)	0.19	(0.10)
Coefficient Of Variation	N/A	470.26	1474.98	1762.32	417.56	1621.89	913.88	1075.21
Mean Deviation	N/A	2.18	1.89	1.41	1.58	1.58	2.29	0.3726
Jensen Alpha	N/A	0.4418	0.0989	(0.05)	0.5202	0.0624	0.1538	0.087
Total Risk Alpha	N/A	0.2424	(0.16)	(0.15)	0.2434	(0.15)	(0.08)	(0.06)
Sortino Ratio	N/A	0.2591	0.0239	(0.0005)	0.2626	0.0081	0.0796	N/A
Downside Variance	N/A	4.4	4.53	4.03	2.9	4.13	8.3	N/A
Standard Deviation	N/A	3.07	2.37	1.91	2.32	2.04	3.1	1.2
Kurtosis	N/A	3.29	(0.08)	2.25	4.49	0.1654	0.602	26.74
Potential Upside	N/A	6.37	4.82	3.02	4.65	3.77	6.59	N/A
Treynor Ratio	N/A	0.3181	0.2906	0.068	2.06	0.2157	0.187	0.679
Maximum Drawdown	N/A	14.55	10.35	9.77	12.95	8.74	15.01	10.45
Variance	N/A	9.42	5.59	3.66	5.4	4.17	9.59	1.45
Market Risk Adjusted Performance	N/A	0.3281	0.3006	0.078	2.07	0.2257	0.197	0.689
Risk Adjusted Performance	N/A	0.1697	0.0585	0.0493	0.1894	0.0533	0.091	0.0746
Skewness	N/A	1.46	0.3837	(0.44)	1.33	0.0835	0.2311	4.41
Semi Deviation	N/A	1.64	1.96	1.91	1.32	1.9	2.55	N/A
Information Ratio	N/A	0.177	0.0215	(0.0005)	0.1924	0.008	0.0741	0.0021
Value At Risk	N/A	(3.40)	(3.21)	(3.29)	(2.50)	(3.25)	(5.14)	N/A
Expected Short fall	N/A	(2.59)	(2.17)	(1.48)	(1.92)	(1.61)	(2.77)	N/A
Downside Deviation	N/A	2.1	2.13	2.01	1.7	2.03	2.88	N/A
Semi Variance	N/A	2.69	3.84	3.67	1.75	3.61	6.53	N/A

Transgene Competition Performance Charts

Five steps to successful analysis of Transgene Competition

Transgene's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Transgene SA in relation to its competition. Transgene's competition analysis typically involves several steps, including:

Identifying the key players in the market: This involves identifying the major competitors of Transgene in the market, both direct and indirect, as well as new entrants and disruptive technologies.
Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Transgene's competitive landscape.
Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Transgene SA, and developing a strategy to address them.
Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.

Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Transgene position

In addition to having Transgene in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run High Dividend Yield ETFs Thematic Idea Now

High Dividend Yield ETFs

ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The High Dividend Yield ETFs theme has 107 constituents at this time.

You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize High Dividend Yield ETFs Theme or any other thematic opportunities.

View All Next

Launch

Other Information on Investing in Transgene Pink Sheet

Transgene financial ratios help investors to determine whether Transgene Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Transgene with respect to the benefits of owning Transgene security.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Transgene Competitors

Specify up to 10 symbols:

Transgene Competition Correlation Matrix

Risk-Adjusted Indicators

Transgene Competitive Analysis

Transgene Competition Performance Charts

Five steps to successful analysis of Transgene Competition

Complement your Transgene position

Did You Try This Idea?

Run High Dividend Yield ETFs Thematic Idea Now

High Dividend Yield ETFs

Other Information on Investing in Transgene Pink Sheet

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY